Literature DB >> 8482817

Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population.

E A Chrischilles1, R B Wallace.   

Abstract

BACKGROUND: Short-term clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) may interfere with the effectiveness of antihypertensive therapies. We studied the joint effects of these two classes of drugs among subjects participating in the cross-sectional baseline interview from a population-based cohort study of community-dwelling elderly.
METHODS: Blood pressure was recorded by interviewers using a standard sphygmomanometer after at least 5 minutes in the sitting position. Two recordings were made in rapid succession, using the first and fifth Korotkoff sounds. The second recording was used for this study. From respondents' medication container labels, interviewers recorded the name and dosage regimen of each medication used during the preceding two weeks.
RESULTS: Persons on antihypertensive therapy taking NSAIDs had systolic blood pressures approximately 5 mmHg higher than those not taking NSAIDs, and were more likely to have systolic blood pressure above 140 mmHg (odds ratio = 2.19, 95% confidence interval 1.33, 3.61). These findings could not be explained by differences between NSAID users and nonusers in age, relative weight, or the type or dose of antihypertensive regimen. No significant effects of NSAIDs were seen for diastolic blood pressure or among persons not taking antihypertensive drugs. When analyses were restricted to non-indomethacin NSAID use, the findings were unchanged.
CONCLUSION: These findings suggest that NSAID use may be an important community reason for loss of pharmacologic control of hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482817     DOI: 10.1093/geronj/48.3.m91

Source DB:  PubMed          Journal:  J Gerontol        ISSN: 0022-1422


  10 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  NSAIDs and blood pressure. Clinical importance for older patients.

Authors:  A G Johnson
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Drug-induced hypertension. Recognition and management in older patients.

Authors:  P W de Leeuw
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 4.  The changing face of hypertension and antihypertensive agents.

Authors:  M E Kitler
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

5.  Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults.

Authors:  Zachary A Marcum; Joseph T Hanlon
Journal:  Ann Longterm Care       Date:  2010

Review 6.  Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective.

Authors:  P W de Leeuw
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 7.  Over-the-counter analgesics in older adults: a call for improved labelling and consumer education.

Authors:  Christianne L Roumie; Marie R Griffin
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Blood pressure effects of naproxcinod in hypertensive patients.

Authors:  Raymond Townsend; Neville Bittar; Jeffrey Rosen; William Smith; Andrea Ramsay; Steven G Chrysant; Robert Weiss; Aldina Pivodic; Brigitte Duquesroix; Jacques Djian
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-01-25       Impact factor: 3.738

9.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

10.  Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors.

Authors:  Deema A Al-Turki; Mohamed A Al-Omar; Laila A Abou-Zeid; Ihsan A Shehata; Mohammed S Al-Awady
Journal:  Saudi Pharm J       Date:  2015-07-26       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.